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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.05.012Objective: We sought to determine whether cytokeratin-positive cells can be de-
tected as markers of lymph node metastasis by using flow cytometry within a time
frame suitable for intraoperative decision making in non–small cell lung cancer.
Methods: Five lymph nodes from each of 20 patients with non–small cell lung
cancer were randomly selected for study. Each node was divided longitudinally into
3 pieces: one piece for flow cytometry, one for immunohistochemical staining, and
the last for conventional hematoxylin and eosin staining. In both flow cytometry and
immunohistochemistry, cytokeratin-positive cells were detected with the fluorescein
isothiocyanate–conjugated anti-cytokeratin antibody AE1/AE3.
Results: Cytokeratin-positive nodes were detected by means of flow cytometry
within 40 minutes. Eight (8%) of the 100 lymph nodes from 4 (20%) of the 20
patients were deemed positive for metastasis on the basis of conventional histologic
examination. By contrast, 33 (33%) lymph nodes from 13 (65%) patients were
deemed positive on the basis of immunohistochemical cytokeratin staining, and 38
(38%) lymph nodes from 14 (70%) patients were deemed positive on the basis of
flow cytometric cytokeratin-positive cell detection. All nodes deemed positive for
metastasis on the basis of conventional and immunohistochemical methods were
also positive on flow cytometry.
Conclusions: Flow cytometry enables rapid intraoperative diagnosis of nodal me-
tastasis in patients with non–small cell lung cancer. Flow cytometric detection of
cytokeratin-positive cells within lymph nodes correlates with their immunohisto-
chemical detection, and its level of sensitivity is greater than that of conventional
histologic staining and about equal to that of immunohistochemical staining.
When a surgeon makes a decision to proceed with further surgical treat-ment for non–small cell lung cancer (NSCLC; eg, mediastinoscopy andextended segmentectomy),1 timely intraoperative determination of the
presence or absence of lymph node metastasis is essential. To that end, lymph node
metastasis is commonly diagnosed intraoperatively on the basis of an examination
of frozen sections. With that technique, however, false-negative results sometimes
occur because micrometastasis goes undetected.
Marchevsky and colleagues2 reported that patients with NSCLC with isolated
tumor cells (ITCs) or micrometastasis in N1 have survival rates similar to those with
pN0 disease, which is consistent with findings reported for patients with breast
cancer. However, those investigators studied only a limited number of patients over
a limited period of time after surgical intervention. By contrast, several other
investigators have reported that survival times among patients with micrometastases
detected immunohistochemically are no better than those among patients with nodal
metastases detected by means of conventional histologic examination.3-7 It is
therefore generally believed that the presence of nodal ITCs or micrometastasis
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This makes it essential that lymph node metastasis is pre-
cisely diagnosed and that false-negative results resulting
from a failure to detect ITCs or micrometastasis are avoided
when making an intraoperative decision about whether to
proceed with further surgical treatment.
Techniques that have been applied to accomplish that
aim include intraoperative immunohistochemical stain-
ing,8-11 imprint cytology,12,13 and reverse transcriptase–
polymerase chain reaction (RT-PCR).14,15 None of these
methods is problem free, however. For that reason, we have
been developing a method that makes use of flow cytometry
(FCM) in the diagnosis of nodal metastasis. In the present
study we tested whether detection of cytokeratin (CK)–
positive cells as markers of nodal metastasis with FCM
could be carried out within a time frame suitable for intra-
operative decision making in NSCLC. We found that FCM
enables rapid intraoperative diagnosis of nodal metastasis
and that the sensitivity of this method is equal to that of
immunohistochemistry.
Materials, Patients, and Methods
Patients
Twenty consecutive patients with NSCLC were enrolled in the
study between April 2004 and December 2004 after obtaining
signed informed consent. Surgically resected specimens were used
under approval of the Institutional Review Boards at Akita Uni-
versity School of Medicine and University Hospital. After a pre-
operative evaluation, the patients were taken to an operating room,
and the standard preparations were made for a thoracotomy, lung
resection, and mediastinal lymph node dissection. Five lymph
nodes from each patient were randomly selected for study. Each
lymph node was divided longitudinally into 3 pieces: one piece
was used for FCM, one for immunohistochemical staining, and the
Figure 1. FCM analysis of cultured lung cancer cells.
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The capsule of the dissected lymph node was removed to avoid
contamination by normal CK-positive cells derived from lung
tissue, after which the cells were dissociated and used to prepare
FCM samples with a commercially available kit (IntraPrep Per-
meabilization Reagent; Coulter cloneImmunotech, Marseille,
France). An anti-CK AE1/AE3 antibody cocktail (DAKO Corp,
Carpinteria, Calif), which recognizes the 56.5-, 50-, 50=-, 48-, and
40-kd keratins of the acidic subfamily (AE1) and all members of
the basic subfamily (AE3), was used to detect CK-positive cells.
The anti-CK antibody was preconjugated with fluorescent dye
(fluorescein isothiocyanate) by using a protein labeling kit (Mo-
lecular Probe, Inc, Eugene, Ore) to avoid the necessity of an
incubation step with a secondary antibody. The FCM samples were
then incubated with the fluorescently labeled antibody (5 g/mL)
for 15 minutes at room temperature, after which the cells were
washed 3 times with phosphate-buffered saline. CK-positive cells
were then detected with an FCM Epics Elite (Coulter Electronics,
Hialeah, Fla). At least 100,000 cells were analyzed for each lymph
node.
Histopathologic Evaluation
Samples from all dissected lymph nodes were sectioned and con-
ventionally examined with hematoxylin and eosin staining. In
addition, other samples were immunohistochemically labeled with
anti-CK AE1/AE3 antibody to detect the presence of micrometas-
tases. A result was considered positive if positive cell clusters or
individual cells with the appropriate tumor cell morphology were
recognized. As proposed by the new American Joint Committee on
Cancer Cancer Staging Manual,16 ITCs were also considered as
positive in this study.
Results
Detection of CK-Positive Cells With FCM
We initially characterized the FCM parameters that were
subsequently used to identify CK-positive cells. Figure 1
A549 and sq19 cancer cells distributed in area A in
lung tumors of our patients. Lymphocytes, by contrast,
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lymphocytes (center and right panels) were subjected to
FCM. Both the forward scatter and side scatter of the tumor
cells were larger than was seen with the lymphocytes, and
the distribution of primary tumor cells exhibited virtually
the same pattern as the cultured tumor cells (Figure 2, left
panel). Gates A (tumor cell area) and B (lymphocyte area)
were defined accordingly. The CK-positive area (gate C)
was defined, taking the results obtained with gate B (lym-
phocyte area) into consideration because lymphocytes are
always CK negative (Figure 2, middle panel). The product
of areas A and C (gate AC) was then used to define the
distribution pattern of CK-positive tumor cells (Figure 2,
right panel).
To confirm the accuracy of the FCM detection of CK-
positive cells, we correlated known numbers of cultured
A549 tumor cells with the numbers of CK-positive cells
counted with FCM (Figure 3). The highly significant (r 
0.99999, P .0001) correlation obtained clearly shows that
we were able to accurately count CK-positive tumor cells
with FCM.
Clinical Evaluation of Metastasis With FCM
The clinical characteristics of the study participants are
summarized in Table 1. CK-positive nodes were detected
intraoperatively within about 40 minutes by using FCM
and the protocol outlined in Table 2. To define the
threshold number of CK-positive cells needed for a
lymph node to be deemed metastasis positive, the FCM
counts were plotted as in Figure 4, after which the values
Figure 2. Detection of CK-positive cells within lymph n
node is depicted in the left panel; note that the gate
cultured lung cancer cells (Figure 1). The gate was
because lymphocytes are always CK negative; area C w
area (middle panel). We defined the product of areas A
scatter; SS, side scatter; FITC, fluorescein isothiocyanwere compared with those obtained from nodes found to
The Journal of Thoracibe immunohistochemically CK positive (eg, Figure 5) or
CK negative. Using this plot, we defined 0.35% as the
threshold value needed for a diagnosis of metastasis. At
that value, there are no false-negative results and only a
minimal number of false-positive results.
Table 3 summarizes our clinical results. Eight (8%)
lymph nodes from 4 (20%) patients were deemed positive
. The distribution of cells from a representative lymph
set in area A according to the pattern obtained with
n lymphocyte area B to define the CK-negative area
en defined as the area not included in the lymphocyte
C as the area of CK-positive tumor cells. FS, Forward
Figure 3. Various numbers of A549 cells were diluted with lym-
phocytes, after which the size of the CK-positive cell fraction
determined with FCM was plotted against the known A549 cell
fraction. The very strong correlation (r  0.99999, P < .0001) is
indicative of our ability to accurately detect and count CK-odes
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contrast, 33 (33%) lymph nodes from 13 (65%) patients
were deemed positive on the basis of immunohistochemical
CK staining, and 38 (38%) nodes from 14 (70%) patients
were deemed positive on the basis of FCM CK-positive cell
detection. All nodes deemed positive by using conventional
and immunohistochemical methods were also positive on
FCM. If results of the immunohistochemistry might be
correct, the sensitivity, specificity, and accuracy of FCM
would be 100% (33/33), 91.2% (62/68), and 96.0% (96/
100), respectively.
TABLE 1. Patient characteristics
Patients 20
Age (y)
Mean 71.5  7.0
Range 56-81
Sex Male: 14
Female: 6
Pathologic stage
Stage IA 6
Stage IB 5
Stage II 1
Stage IIIA 4
Stage IIIB 1
Stage IV 3
Tumor location
RUL 7
RML 1
RLL 4
LUL 3
LLL 5
Tumor size (mm)
Mean 26.8  13.6
Range 10-60
Histologic type
Ad 12
Sq 8
RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe LUL,
left upper lobe, LLL, left lower lobe; ad, adenocarcinoma; sq, squamous cell
carcinoma.
TABLE 2. Timetable of cytokeratin-positive cell detection
with FCM
Time Procedure
5 min Preparation of lymph node single-cell suspension
10 min Hemolysis and cell permeabilization
15 min Immunofluorescent staining with antibody AE1/
AE3
5 min FCM
Total 
40 minFCM, Flow cytometry.
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The present findings suggest (1) that FCM can be used to
rapidly identify CK-positive lymph nodes in patients with
Figure 4. Threshold value for FCM detection of micrometastasis.
The percentages of CK-positive cells were plotted against the
percentages of immunohistochemically positive (IHC[]) and
negative (IHC[]) cells. Filled and open circles depict hematox-
ylin and eosin–positive and hematoxylin and eosin–negative
staining, respectively. The threshold line was drawn below the
immunohistochemically positive cells at 0.35%. On the basis of
this plot, we deemed micrometastasis to be present when the
percentage of CK-positive cells determined by means of FCM was
more than 0.35%.
Figure 5. Detection of micrometastasis with CK immunohisto-
chemistry. After labeling lymph nodes with the anti-CK antibody
AE1/AE3, the result was considered positive if individual cells or
clusters of cells with the appropriate tumor cell morphology were
recognized. As proposed by the new American Joint Committee
on Cancer Cancer Staging Manual, isolated tumor cells were also
diagnosed as metastasis.
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correlates with immunohistochemical detection, and (3) that
FCM is a more sensitive tool for detecting nodal metastasis
than conventional histologic evaluation, with a level of
sensitivity about equal to that of immunohistochemical ex-
amination. It thus appears that we might be able to apply
FCM detection of CK-positive cells for intraoperative diag-
nosis of nodal metastasis in NSCLC. However, the pro-
posed threshold value (0.35%, Figure 4) can be applied only
to our FCM. If other investigators will follow our method,
the cut-off value for each FCM must be defined by using
true-negative lymph nodes from patients with benign dis-
ease (negative control) and true-positive lymph nodes from
patients with lung cancer (positive control). For standard-
ization and maintenance of the protocol, the setting of each
FCM must be sometimes adjusted with negative and posi-
tive controls.
Conventional analysis of frozen tissue sections enables
very rapid diagnosis, within 20 minutes at most institu-
tions,17 but the sensitivity of this method for detecting
micrometastasis is comparatively low. By contrast, the sen-
sitivity of RT-PCR assays, which have been applied to the
diagnosis of lymph node metastasis outside the surgical
setting, is very high.14,15 Unfortunately, the amount of time
commonly required to conduct such assays makes them
unsuitable for intraoperative decision making. Several in-
vestigators have been trying to reduce the time required for
RT-PCR assays, however. For instance, Raja and associ-
ates18 have developed a rapid and quantitative RT-PCR
assay that they reported could be used to detect microme-
tastasis within about 30 minutes. This approach addresses
the problem of time, but it does not address a second
potential problem: because of its very high sensitivity, con-
ventional RT-PCR produces a comparatively high number
of false-positive reactions.19
Although immunohistochemical staining also commonly
requires several hours to complete, several recently de-
scribed techniques enable immunohistochemical staining to
be accomplished within only 12 to 30 minutes.8-11 In addi-
tion, imprint cytology is sometimes applied for the diagno-
sis of malignancy and nodal metastasis because it is conve-
nient and can be done quickly. But although the accuracy of
TABLE 3. Diagnosis of micrometastasis with FCM, IHC, and
HE
Methods N patient N node
FCM 14/20 (70%) 38/100 (38%)
IHC 13/20 (65%) 33/100 (33%)
HE 4/20 (20%) 8/100 (8%)
FCM, Flow cytometry; IHC, immunohistochemistry; HE, hematoxylin and
eosin.imprint cytology is often sufficient to warrant its use for
The Journal of Thoraciintraoperative assessment of nodal metastasis instead of
frozen sections,20 it is not sufficiently sensitive to detect
micrometastases.21,22 To increase its sensitivity, however,
Munakata and coworkers12 combined imprint cytology with
immunofluorescent labeling of CK and obtained results
similar to those obtained with immunohistochemistry alone.
Thus both of these techniques are potentially applicable for
intraoperative diagnosis of nodal metastasis and decision
making.
In the present study we describe an additional new
method for the intraoperative diagnosis of nodal microme-
tastasis. We were able to detect CK-positive nodes within
40 minutes using FCM, which is within about the same time
frame as the aforementioned methods. To further confirm
the feasibility of CK detection with FCM for the diagnosis
of micrometastasis, in a future investigation, we will com-
pare the FCM method with other rapid methods for detect-
ing micrometastasis.
The use of FCM to detect metastasis was first reported
by Joensuu and colleagues,23 who used DNA aneuploidy
as an indicator of metastasis. In the present study we
detected the presence of CK-positive cells within lymph
nodes as an indicator of micrometastasis, which means
that we need to consider the possibility of false-positive
results very carefully. In many instances microscopic
evaluation of immunohistochemically stained sections
has revealed CK-positive interstitial reticulum cells,
sometimes leading to false-positive staining of sinus lin-
ing cells.24 Although such staining is easily recognized
morphologically, no morphologic checks can be made to
control for false-positive CK staining when using the
FCM method. To avoid these cells, Leers and associ-
ates25 combined multiparameter FCM detection of me-
tastasis with CK staining and DNA aneuploidy detection
in formalin-fixed, paraffin-embedded lymph nodes. We
did not stain DNA in our present study because our final
goal is to be able to provide the surgeon with this critical
information within a time frame that enables important
surgical decisions to be made intraoperatively. Instead,
we found that nontumorous CK-positive cells could be
omitted by using an appropriate threshold value that led
to no false-negative results and a minimal number of
false-positive results (Figure 4). If results of the immu-
nohistochemistry were correct, the false-positive rate
would be 8.1% (5/67). The importance of false-positive
or false-negative findings and their effect on patient care
will depend on the treatment offered on the basis of this
finding. If detection of micrometastases will mandate that
the surgeon performs a complete lymph node dissection
versus a node sampling, then greater importance should
be placed on minimizing false-negative results. On the
other hand, if the patient will be denied or offered a
limited resection on the basis of the presence of a positive
c and Cardiovascular Surgery ● Volume 130, Number 3 757
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accepted. To confirm this finding, we intend to compare
our FCM method with multiparameter FCM detection in
a future study.
In summary, we have developed a rapid intraoperative
FCM technique for the diagnosis of lymph node metastasis.
This method appears to be sensitive enough to detect mi-
crometastases, although only a limited number of patients
were investigated. Consequently, further investigation will
be required to confirm the feasibility of this method.
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